A Consumer's Guide to Subgroup Analyses

References

• 1. Pocock S, Hughes M, and Lee R. Statistical problems in the reporting of clinical trials. N Engl J Med. 1987;317:426-32. CrossrefMedlineGoogle Scholar
• 2. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi Nell'Infarcto Miocardico (GISSI). Lancet. 1986;2:397-402. CrossrefMedlineGoogle Scholar
• 3. Lee T, Weisberg M, Brand D, Rouan G, and Goldman L. Candidates for thrombolysis among emergency room patients with acute chest pain. Ann Intern Med. 1989;110:957-62. LinkGoogle Scholar
• 4. Tate D and Dehmer G. New challenges for thrombolytic therapy. Ann Intern Med. 1989;110:953-5. LinkGoogle Scholar
• 5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-60. MedlineGoogle Scholar
• 6. Yusuf S, Collins R, and Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409-20. CrossrefMedlineGoogle Scholar
• 7. . Treatment of Early Breast Cancer. v 1. Worldwide evidence 1985-1990. New York: Oxford University Press; 1990:7-9. Google Scholar
• 8. Sackett D, Haynes R, and Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown & Company; 1985. Google Scholar
• 9. Chalmers T, Smith H, Blackburn B, Silverman B, Schoeder B, and Reitman D. A method for assessing the quality of a randomized control trial. Controlled Clin Trials. 1981;2:31-49. CrossrefMedlineGoogle Scholar
• 10. Fletcher R, Fletcher S, and Wagner E. Clinical Epidemiology. 2d ed. Baltimore: Williams & Wilkins, 1988:185-6. Google Scholar
• 11. Feinstein A. Clinical Epidemiology. Philadelphia: W.B. Saunders; 1985:306-7, 516-7. Google Scholar
• 12. Goldman L and Feinstein A. Anticoagulants and myocardial infarction. The problems of pooling, drowning, and floating. Ann Intern Med. 1979;90:92-4. LinkGoogle Scholar
• 13. Furberg C and Morgan T. Lessons from overviews of cardiovascular trials. Stat Med. 1987;6:295-306. CrossrefMedlineGoogle Scholar
• 14. Horwitz R. Complexity and contradiction in clinical trial research. Am J Med. 1987;82:498-510. CrossrefMedlineGoogle Scholar
• 15. Buyse M. Analysis of clinical trial outcomes: some comments on subgroup analyses. Controlled Clin Trials. 1989;10:187S-194S. CrossrefMedlineGoogle Scholar
• 16. Bulpitt C. Subgroup analysis. Lancet. 1988;2:31-4. CrossrefMedlineGoogle Scholar
• 17. Byar D. Assessing apparent treatment—covariate interactions in randomized clinical trials. Stat Med. 1985;4:255-63. CrossrefMedlineGoogle Scholar
• 18. Shuster J and van Eys J. Interaction between prognostic factors and treatment. Controlled Clin Trials. 1983;4:209-14. CrossrefMedlineGoogle Scholar
• 19. Kleinbaum D, Kupper L, and Morgenstern H eds. Interaction, effect modification, and synergism. In: Epidemiologic Research. New York: Van Nostrand Reinhold Company, 1982;403-18. Google Scholar
• 20. Last J. A Dictionary of Epidemiology. 2d ed. New York: Oxford University Press; 1988:41, 66, 127. Google Scholar
• 21. Yusuf S, Wittes J, and Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol. 1990;66:220-2. CrossrefMedlineGoogle Scholar
• 22. Bailey K. Inter-study differences: how should they influence the interpretation and analysis of results? Stat Med. 1987;6:351-8. CrossrefMedlineGoogle Scholar
• 23. Davis C and Leffingwell D. Empirical Bayes estimates of subgroup effects in clinical trials. Controlled Clin Trials. 1990;11:37-42. CrossrefMedlineGoogle Scholar
• 24. Sackett D. Clinical diagnosis and the clinical laboratory. Clin Invest Med. 1978;1:37-43. MedlineGoogle Scholar
• 25. Yusuf S, Peto R, Lewis J, Collins R, and Sleight T. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovas Dis. 1985;27:335-71. CrossrefMedlineGoogle Scholar
• 26. Peto R. Why do we need systematic overviews of randomized trials? Stat Med. 1987;6:233-4. CrossrefMedlineGoogle Scholar
• 27. Schneider B. Analysis of clinical trial outcomes: alternative approaches to subgroup analysis. Controlled Clin Trials. 1989;10:176S-186S. CrossrefMedlineGoogle Scholar
• 28. Breslow N and Day N. Analysis of Case-Control Studies. v 1 of Statistical Methods of Cancer Research. Lyon: IARC Scientific Publications; 1980:122-59. Google Scholar
• 29. Donner A. A Bayesian approach to the interpretation of subgroup results in clinical trials. J Chronic Dis. 1982;34:429-35. CrossrefGoogle Scholar
• 30. Louis T. Estimating a population parameter values using Bayes and empirical Bayes methods. J Am Stat Assoc. 1984;79:393-8. CrossrefGoogle Scholar
• 31. Beach M and Meier P. Choosing covariates in the analysis of clinical trials. Controlled Clin Trials. 1989;10:161S-175S. CrossrefMedlineGoogle Scholar
• 32. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978;299:53-9. CrossrefMedlineGoogle Scholar
• 33. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J [Clin Res]. 1988;296:320-31. CrossrefMedlineGoogle Scholar
• 34. Canner P, Huang Y, and Meinert C. On the detection of outlier clinics in medical trials: I. Practical considerations. Controlled Clin Trials. 1981;2:231-40. CrossrefMedlineGoogle Scholar
• 35. Lee D, Johnson R, Bingham J, Leahy M, Dinsmore R, and Goroll A. Heart failure in outpatients. N Engl J Med. 1982;306:699-705. CrossrefMedlineGoogle Scholar
• 36. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Beta-blocker Heart Attack Trial Research Group. JAMA. 1982;247:1707-14. CrossrefMedlineGoogle Scholar
• 37. Furberg C and Byington R. What do subgroup analyses reveal about differential response to beta-blocker therapy? Circulation. 1983;67:198-1101. MedlineGoogle Scholar
• 38. Cook D, Witt L, Cook R, and Guyatt G. Stress ulcer prophylaxis in the critically ill—a meta-analysis. Am J Med. [In press.] Google Scholar
• 39. Guyatt G, Sullivan M, Fallen E, Tihal H, Rideout E, and Halcrow S. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371-5. CrossrefMedlineGoogle Scholar
• 40. Jaeschke R, Oxman A, and Guyatt G. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med. 1990;88:279-86. CrossrefMedlineGoogle Scholar
• 41. Stieb D, Frayha H, Oxman A, Shannon H, Hutchison B, and Crombie F. Effectiveness of Haemophilus influenzae type b vaccines. Can Med Assoc J. 1990;142:719-33. Google Scholar
• 42. Kelton J, Hirsh J, Carter C, and Buchanan M. Sex differences in the antithrombotic effect of aspirin. Blood. 1978;52;1073-6. CrossrefMedlineGoogle Scholar
• 43. Hill A. Principles of Medical Statistics. 9th ed. London: Lancet; 1971:312-20. Google Scholar